BMRN News and Press, BioMarin Pharmaceutical Inc. From 05/08/24

2024-05-08 06:55:36 ET Summary Ascendis Pharma is expected to achieve cash flow break even by the end of 2024, driven by its core franchise of medicines for rare endocrinology conditions. The company's approved drug, Skytrofa, has shown strong sales and has the potential to be a b...

2024-05-06 09:21:31 ET More on BioMarin Pharmaceutical BioMarin Pharmaceutical, Inc. (BMRN) Q1 2024 Earnings Call Transcript BioMarin Pharmaceutical Inc. 2024 Q1 - Results - Earnings Call Presentation BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth ...

New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting PR Newswire Investigator-Sponsored Phase 2 Study Demonstrated Positive Results in Children with Noonan Syndrome, ...

2024-04-25 15:46:04 ET More on etc. Covenant Logistics Group, Inc. (CVLG) Q1 2024 Earnings Call Transcript Q1 2024 Sales/ Trading Statement Call Choice Properties Real Estate Investment Trust (PPRQF) Q1 2024 Earnings Call Transcript AGCO declares $0.29 divide...

2024-04-24 20:50:24 ET BioMarin Pharmaceutical, Inc. (BMRN) Q1 2024 Earnings Conference Call April 24, 2024 04:30 PM ET Company Participants Traci McCarty - Head of IR Alexander Hardy - President & CEO Henry Fuchs - President, Worldwide Research & Develop...

2024-04-24 17:22:19 ET Read the full article on Seeking Alpha For further details see: BioMarin updated 2024 guidance sees EPS raise, but no change to revenue

2024-04-24 16:03:10 ET More on BioMarin Pharmaceutical BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth BioMarin Pharmaceutical Inc. 2023 Q4 - Results - Earnings Call Presentation BioMarin Pharmaceutical, Inc. (BMRN) Q4 2023 Earnings Call Transcript ...

BioMarin Reports Record Financial Results for the First Quarter 2024 PR Newswire First Quarter 2024 Total Revenues of $649 Million (+9% Y/Y and +13% at Constant Currency Y/Y); GAAP Diluted Earnings per Share (EPS) of $0.46 (+70% Y/Y) and Non-GAAP Diluted Earnings pe...

Pegasystems Inc. (PEGA) is expected to report $0.2 for Q1 2024 Masco Corporation (MAS) is expected to report $0.87 for Q1 2024 Avery Dennison Corporation (AVY) is expected to report $2.15 for Q1 2024 Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A...

2024-04-23 17:20:33 ET More on BioMarin Pharmaceutical BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth BioMarin Pharmaceutical Inc. 2023 Q4 - Results - Earnings Call Presentation BioMarin Pharmaceutical, Inc. (BMRN) Q4 2023 Earnings Call Transcript ...